Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer
- Sponsor
- Institut Paoli-Calmettes
- Study ID
- NCT01190345
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- bevacizumab — DRUGPatients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
- no bevacizumab — DRUGno bevacizumab
Study Details
The purpose of this study is to evaluate anti-cancer stem cell (CSC) activity (measured by the amount of Aldehyde dehydrogenase 1/ALDH1+ cells before and after treatment) of pre-operative bevacizumab in combination with conventional chemotherapy in breast cancer receiving neo-adjuvant treatment, compared to a control arm receiving chemotherapy alone.
Key Dates
- First listed
- Aug 27, 2010
- Start date
- May 31, 2010
- Status verified
- Aug 2018
- Primary completion
- Jul 24, 2012
- Completion
- Oct 6, 2017
Study Design
- Enrollment
- 75 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: WITH bevacizumabbevacizumab 15 mg/kg on day 1 of each cycle : 4 cycles of 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days. Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections.
- Active Comparator: without bevacizumab4 cycles 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV of (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days. Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections.
Primary Outcome Measure
Measure of the anti-cancer stem cell activity [ Time Frame: 4 months ]
Related Studies
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Harvesting Cells for Experimental Cancer TreatmentsEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast CancerRecruiting · Carol Fabian, MD · Kansas City, Kansas
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland